(A) Purified CLL cells (CD19 + ) were cultured on BMSCs or EL08-1D2 cells for 5 days, CLL cells were then physically removed from stromal cells by repeated washing. Stromal cells were further purified using anti-CD19-magnetic beads. For flow cytometry analysis, cells were stained with an anti-CD19 antibody (y-axis, side scatter on x-axis).
(B) CLL cells or CD19-purified or CD5-purified B cells from the peripheral blood of healthy donors were co-cultured on EL08-1D2 cells. After 5 days apoptotic cells were analyzed by Annexin-V/PI staining (CLL: n=5; CD19 + : n=3 and CD5 + : n=3, error bars show mean ± SEM). (A) EL08-1D2 cells were irradiated or cultured in the presence of indicated compounds, for the same length of time as in the corresponding experiments. Apoptotic cells were detected by flow cytometry of fixed cells, stained with PI (sub-G1-fraction). Cycloheximide was used as a positive control. Error bars show mean ± SEM.
(B) Primary CLL cells from ZAP70 positive and negative patient samples (indicated by V-, and Pnumbers) were co-cultured on EL08-1D2 cells for 5 days before the expression of PKC-II was analyzed in stromal cells by immunoblotting.
(C) PKC-II expression in EL08-1D2 cells (Sca-1 + ) was assessed by immunofluorescence after 5 days of culture with (a-d) or without CLL cells (e-h). To visualize CLL cells they were incompletely removed at the end of the experiment (white arrows in (i)). (The red channel was focused so as to capture the perinuclear PKC-II).
(D) Primary CLL cells were cultured in medium or medium derived from EL08-1D2 mono-cultures (CM(EL08-1D2)) or from 5 day-EL08-1D2/CLL co-cultures (CM(EL08-1D2+CLL)). After 5 days, apoptotic CLL cells were analyzed by Annexin-V/PI staining. (n=6, error bars show mean ± SEM).
(E) Confluent monolayers of EL08-1D2 cells or hBMSCs were irradiated (30Gy and 15Gy respectively) before co-culturing with CLL cells. Percentage of apoptotic CLL cells was analyzed after 5 days. (n=6, error bars show mean ± SEM). (A) CLL cells were cultured on BMSCs from wild-type or Prkcb -/-animals according to the experiment depicted in Figure 3D . PKC-II expression in BMSCs was assessed by immunobloting after 5 days.
(B) The expression of PKC-II was analyzed by western blotting in control Prkcb -/-BMSCs (-) or in Prkcb -/-BMSCs transduced with empty vector virus or virus expressing PKC-II wild-type or mutant (K371R) cDNA. ZAP70 positivity in case >20% of CLL cells were positive by flow cytometry analysis * Genomic DNA was sequenced for Notch1 (exons 25-34), MyD88 (exons 4-5) and TP53 (exons 4-11) mutations.  %Annexin-V positive CLL cells (cultured on PKC- deficient stromal cells -cultured on PKC- wild type stroma) n.a.= data not available (A) CLL cells were cultured on hBMSCs for 5 days, activation of NF-B in hBMSCs was analyzed by EMSA performed on nuclear proteins (n=3).
(B) Primary CLL cells were cultured on EL08-1D2 cells transfected with a siRNA directed against PKC-II or a control siRNA. Z.vad.fmk (100 μM) was added to the co-culture as indicated. After 5 days, apoptotic CLL cells were analyzed by Annexin-V/PI staining. Bars represent the percentage of apoptosis protection compared to cells cultured in medium (n=3, error bars show mean ± SEM).
(C) NF-B activation was analyzed by EMSA from EL08-1D2/CLL co-cultures depicted in (B).
(D) Western blots depicted in Figure 4C were analyzed by densitometry using the ImageJ ® software. Fold-increase indicates the amount of nuclear p50, p65 and cRel after CLL contact relative to EL08-1D2 cells not co-cultured with CLL cells. Error bars show mean ± SEM. (A) 2x10 7 splenic PBMCs from a diseased TCL1tg mouse (donor#1) were transplanted into syngeneic wild-type or Prkcb -/-mice. Mice in both cohorts were followed for signs of illness and killed when moribund. 
Supplemental Experimental Procedures
Reagents and Antibodies Polyclonal antibodies specific for PKC-II (clone C-18), PKC-I (clone C-16), NF-B p50 (NLS, sc-114), NF-B p65 (clone C-20), cRel (sc-71) and Bcl10 (C78F1) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The monoclonal antibodies ZAP70 (clone 29) were purchased from BD Transduction Laboratories (Heidelberg, Germany) and PKC- (2056) was obtained from New England Biolabs (Frankfurt am Main, Germany). NEMO and actin were immunoblotted with mouse IKK (clone 72C627) (Millipore, CA, USA) and -actin (clone AC-15, Sigma Deisenhofen, Germany). Immunofluorescence analyses were performed using anti-RhoA (67B9) (New England Biolabs Frankfurt am Main, Germany), anti-SMA (ab5694) (Abcam, Cambridge, UK), anti-Phalloidin-FITC (Invitrogen, Oregon, USA), anti-Sca1 (clone D7) (eBioscience, Frankfurt, Germany) and To-Pro3 (Invitrogen, Darmstadt, Germany). For immunohistochemistry (Figure 6D ), the following antibodies were used: b220 (clone RA3-6B2) and CD5 (clone 53-7.3) from Pharmingen (Schwerte, Germany), CD3 (clone sp7) from Innovative Diagnostic System (Hamburg, Germany) and mib-1 (clone sp6) from Thermo scientific (Schwerte, Germany).
The cytotoxic agents doxorubicin and cyclohexamide were purchased from Sigma (Deisenhofen, Germany). Enzastaurin is provided by LC Labs, (Woburn, MA, USA). The IKK2 inhibitor was a kind gift from Karl Ziegelbauer (Bayer Schering Pharma AG).
Cells and culturing conditions
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples by centrifugation over a Ficoll-Hypaque layer (Biochrom, Berlin, Germany) of 1.077 g/ml density. For separation of CLL B cells, PBMC were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450, Dynal, Oslo, Norway) according to the manufacturer's instructions. After separation B cells from CLL patients were >98% pure as assessed by direct immunofluorescence. Cells were harvested under ice-cold conditions and were cultured in RPMI 1640 (Gibco, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS) penicillin/streptomycin 50 U/ml, Na-pyruvate 1mM, L-glutamine 2 mM, L-asparagine 20 mg/ml, 2-mercaptoethanol 0.05mM, HEPES 10mM and MEM non-essential amino acids (Gibco).
For separation of peripheral blood B cells from healthy donors, PBMNCs were incubated with anti-CD19 magnetic beads and isolated B cells were released from CD19 beads by using CD19 DETACHaBEAD (Invitrogene, Karlsruhr, Germany) according to the manufacturer's instructions.
For isolation of CD5
+ B cells from the peripheral blood of healthy donors, PBMC were isolated by Ficoll density gradient centrifugation (Amersham, Freiburg, Germany) and subsequently, CD19 + B cells were negatively enriched by the EasySep® Human B Cell Enrichment Kit 19054 (Stemcell, Cologne, Germany). CD5 + B cells were then enriched by anti-CD5-APC (UCHT2) and anti-APC MicroBeads (Miltenyi) to a purity of >70%. Antibodies were purchased from BD Biosciences (Becton Dickinson, Heidelberg, Germany.
The murine embryonic liver cells EL08-1D2 and all primary mouse bone marrow stromal cell cultures were cultured in MEM Alpha + GlutaMAX medium (Invitrogen) supplemented with 10% fetal calf serum (PAA, Cölbe, Germany), 10% horse Serum (StemCell technologies, Grenoble, France) 10 µM 2-mercaptoethanol and 1% penicillin/ streptomycin (Gibco). These cells were grown on 0.1% gelatine coated cell culture plates. RPMI medium containing 10% fetal bovine serum, 10% horse serum, 10 µM 2-mercaptoethanol, 1 mM sodium pyruvate, non-essential amino acids, 2 mM L-glutamine, 10 mM HEPES, 10 mg/ml L-asparagine, 100 U/ml penicillin/streptomycin and 10 -6 M hydrocortisone was used for the primary human stromal cells. Human Umbilical Vein Endothelial Cells (HUVEC) were maintained in EBM-2 (+Bullet-Kit) medium (LONZA, MD, USA), the murine osteoplastic cell line MC3T3 in -MEM medium supplemented with 10% FCS and the human primary osteoblasts (hOB) in Osteoblast Growth medium + SupplementMix (Promocell, Heidelberg, Germany). All cells were cultured at 37°C and 5% CO2 in a fully humidified atmosphere.
Cytokine array
Supernatants from EL08-D1 cells and co-cultures were centrifuged to discharge cells and cell debris. These supernatants were analyzed concerning their content of cytokines using a RayBio Mouse Cytokine Antibody Array (RayBiotech, Inc., Georgia, USA). After blocking the provided membranes overnight, they were incubated with the samples at 4°C overnight. The following washing steps, biotinconjugated-antibody incubation and detection with HRP-conjugated streptavidin were prepared according to the manufacturer's instructions.
Microarray profiling and data analysis
Primary CLL cells were separated from co-cultures with stromal cells by repeated washing steps with PBS (see Figure S1A ). Flow-cytometry analysis indicated that more than 99% CD5 + CD19 + cells were successfully isolated from CLL-stroma-co-cultures. Subsequently, single cell suspensions were treated with magnetic anti-CD19 beads to allow removal of the remaining CLL cells. Total RNA was extracted from stromal cells (EL08-1D2 or mBMSCs), which had been co-cultured with CLL cells for 5 days or cultured without CLL, using the miRNeasy Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer's instruction. To remove remaining genomic DNA, RNA was treated with RNase-free DNase Set (Quiagen).
For microarray analyses, we used the Affymetrix GeneChip platform employing the Express Kit protocol for sample preparation and microarray hybridization. Total RNA (200ng) was converted into biotinylated cRNA, purified, fragmented and hybridized to MG-430_2.0 microarrays (Affymetrix). The arrays were washed and stained according to the manufacturer's recommendation and finally scanned in a GeneChip scanner 3000 (Affymetrix). Arrays were processed in two batches consisting of one control and two or four co-cultured samples. Both batches were analyzed separately.
Array images were processed to determine signals and detection calls (Present, Absent, Marginal) for each probeset using the Affymetrix GCOS1.4 software (MAS 5.0 statistical algorithm). Arrays were scaled across all probesets to an average intensity of 1000 to compensate for variations in the amount and quality of the cRNA samples and other experimental variables of non-biological origin. Pairwise comparisons of co-cultured versus control samples were carried out with GCOS1.4, which calculates for each probeset the significance (change p-value) of each change in gene expression based on a Wilcoxon ranking test. By comparing the change p-value against thresholds empirically determined by Affymetrix, a Change Call (I, MI, NC, MD or D) is generated, indicating "Increased", "Marginally Increased", "No Change", "Marginal Decreased" or "Decreased" expression in the experimental samples. To limit the number of false positives, we restricted further target identification to those probesets, which received at least one present detection call in the treated/control pair. Only probesets exhibiting a significant increase or decrease in the comparison analysis and at least one Present detection call per pair were considered as potentially regulated targets. Probesets identified as consistently up-or down-regulated in ≥ 5 of the 6 (83%- Figure 1D ) or 7 of 7 (100%- Figure 5A ) pairwise comparisons of co-cultured versus control cultures were considered as consistent targets.
Immunofluorescence of EL08-1D2 cells EL08-1D2 cells were plated on 6cm dishes with glass cover slips, previously coated with 0.1% gelatin and Poly-L-Lysine. After 24 hr primary CLL cells were cultured on stromal cells. After 5 days CLL cells were carefully removed, stromal cells washed with PBS and cover slips were transferred to 6-well culture plates, rinsed again 3 times with PBS, and fixed with 4% PFA (0.5% PFA in case of phalloidin staining) for 15 min at room temperature. Cells were permeabilized with 0.1% Triton X-100 and blocked with 10% FCS in PBS for 1h. Rinsing cells three times with PBS terminated permiabilization. Primary antibodies diluted in blocking buffer (10% FCS, 0.1% Triton X-100 in PBS) were added and incubated overnight at 4°C in a humid chamber. Samples were rinsed three times with PBS prior to the addition of the secondary antibody, applied in blocking buffer, for 2 hr at room temperature. Nuclei were counterstained with 100 µM To-Pro3 for 1h at room temperature. After rinsing with PBS cover slips were mounted on microscope slides in the Slow Fade Gold antifade reagent (Invitrogen) and kept dry at -20°C. Confocal laser scanning microscopy was carried out using a LSM510 confocal laser microscope (Zeiss).
